Evidence map›Paper›PMID 41471288›Full record

ArticlePharmaceuticals (Basel, Switzerland)2025

Neuroprotective Effects of Fluoxetine Derivative 4-[3-Oxo-3-(2-trifluoromethyl-phenyl)-propyl]-morpholinium Chloride (OTPM) as a Potent Modulator of Motor Deficits and Neuroinflammatory Pathways in LPS-Induced BV-2 Microglial Cells and MPTP-Induced Parkinsonian Models.

Seong-Mook Kang, Rengasamy Balakrishnan, Hyun Myung Ko, Ju-Young Park, Hemant Kumar, Byungwook Kim, Sung-Hwa Yoon, Dong-Kug Choi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Seong-Mook KangDepartment of Applied Life Sciences, BK21 Program, Graduate School, Konkuk University, Chungju 27478, Republic of Korea.
Rengasamy BalakrishnanDepartment of Biotechnology, Research Institute of Inflammatory Disease (RID), College of Biomedical and Health Science, Konkuk University, Chungju 27478, Republic of Korea.
Hyun Myung KoDepartment of Applied Life Sciences, BK21 Program, Graduate School, Konkuk University, Chungju 27478, Republic of Korea.
Ju-Young ParkMolecular Science and Technology Research Center, Ajou University, Suwon 16499, Republic of Korea.
Hemant KumarDepartment of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad 382355, India.
Byungwook KimDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.ORCID 0000-0001-8390-7713
Sung-Hwa YoonDepartment of Molecular Science and Technology, Ajou University, Suwon 16499, Republic of Korea.
Dong-Kug ChoiDepartment of Applied Life Sciences, BK21 Program, Graduate School, Konkuk University, Chungju 27478, Republic of Korea.ORCID 0000-0001-7041-1524

Funding

National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) RS-2023-00208350
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

microglial activationMPTPneuroinflammationneuroprotectionOTPMParkinson’s disease

Identifiers

PMID41471288
PMCPMC12735652

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.